5[1]Igarashi M.A new therapy for pelvic endometriosis and uterine adenomyosis: local effect of vaginal and intrauterine danazol application.Asia Oceania J Obstet Gynecol,1990,16: 1-3.
6[3]Fedele L,Bianchi S,Raffaelli R,et al.Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device.Fertil Steril,1997,68: 426-429.
7[4]Fong YF,Singh K.Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system.Contraception,1999,60: 173-174.
8[5]Lahteenmaki P,Rauramo I,Backman T.The levonorgestrel intrauterine system in contraception.Steroid,2000,65: 693-697.
9Kurumaki H,Toivonen J,Lahteenmaki P,et al.Pituitary and ovarian function and clinical performance during the use of a levonorgestrel-releasing intracervical contraceptive device.Contraception,1984,29:31.
10Xiao BL,Zhou LY,Zhang XL,et al,Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device.Contraception,1990,41(4):353-362.
1Salim R,Riris S ,Saab W ,et al.Adenomyosis reduces preg- nancy rates in infertile women undergoing IVF[J].Reprod Biomed Online, 2012,25 (3) : 273-277.
2Jung DC,Kim MD,Oh YT,et aLPrediction of early re- sponse to uterine arterial embolisation of adenomyosis: value of T2 signal intensity ratio of adenomyosis [J].Eur Radiol, 2012,22 (9) : 2044-2049.
3Fan TY,Zhang L,Chen W,et al.Feasibility of MRI-guided high intensity focused ultrasound treatment for adeno- myosis[J].Eur J Radiol, 2012,81 ( 11 ) :3624-3630.
